{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "CANCER HARM ASSESSMENT, MITIGATION AND REVIEW POLICY"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MSEPO-21008"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Policy"
                    },
                    {
                        "text": "To be followed by:"
                    },
                    {
                        "text": "All staff working in clinical divisions"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "22 February 2021"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "21 February 2024"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "NHS England Gateway reference: 04237 Managing long waiting cancer patients"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Cancer Services"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Catherine O'Doherty, Group Clinical Director for Cancer"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2612 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2610 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "MSE Cancer Committee"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Stuart Harris, Medical Director Care Group 3"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "09 February 2021"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group)"
                    },
                    {
                        "text": "March 21"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612 Trust Intranet \u2610 Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 1,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 4,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 8,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Emma Chaplin"
                    },
                    {
                        "text": "Associate Director for Nursing for Cancer MSE"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "MSE Cancer Committee"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Yvonne Blucher"
                    },
                    {
                        "text": "Managing Director Care Group 3"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Clare Burns"
                    },
                    {
                        "text": "Operations Director for Cancer and Ophthalmology"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Stuart Harris"
                    },
                    {
                        "text": "Medical Director Care Group 3"
                    },
                    {
                        "text": "04 February 2021"
                    },
                    {
                        "text": "Denise Townsend"
                    },
                    {
                        "text": "Governance Director MSE"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Sharon Murrell"
                    },
                    {
                        "text": "MSE Head of Patient Safety"
                    },
                    {
                        "text": "11 December 2020"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "Cancer Harm Review Process MSESOP-2011 Cancer Access Policy CM93 Procedure for the reporting and management of incidents and serious Incidents (SIs) MSEPO-19015"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 7,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Catherine O'Doherty"
                    },
                    {
                        "text": "New policy"
                    },
                    {
                        "text": "22 February 2021"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Contents"
            },
            "type": "ListItem",
            "sequence_num": 8
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Introduction ................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "Scope............................................................................................................................ 5"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Definitions ..................................................................................................................... 5"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Role & Responsibilities within the Trust ........................................................................ 6"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Key Elements of Policy / Guideline ............................................................................... 8"
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Training Requirements................................................................................................ 10"
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Monitoring and Audit ................................................................................................... 10"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Equality Impact Assessment ....................................................................................... 11"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "References ................................................................................................................. 11 Appendix 1: Cancer Harm Review Process ....................................................................... 12 Appendix 2: Cancer Harm Review Reporting Structure ..................................................... 13 Appendix 3: Harm definitions and interpretation (NRLS).................................................... 14 Appendix 4: Preliminary Equality Analysis ......................................................................... 16"
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Cancer constitutional standards were introduced in 2009 to ensure that patients received timely diagnosis and treatment with the aim of improving cancer survival and ensuring as good a patient experience as possible."
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "Cancer constitutional standards require that, with a small number of exceptions, patients referred to hospital on an urgent cancer pathway by their general practitioner, or whose pathway is \u2018upgraded' to this by a secondary care clinician, should receive their first cancer treatment within 62 days of the referral being received."
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "These standards also require that patients should receive first treatment within 31 days of the decision to treat being made."
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "Exceptions to this are for children's cancer, testicular cancer and acute leukaemia where first treatment should be within 31 days of referral, reflecting the more urgent need for treatment in these conditions."
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "For patients whose treatment is delayed beyond the times set by the constitutional standards, it is important to understand whether or not they may have come to harm as a result of the delay"
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.6,
                "text": "This is usually done by assessing whether potential harm has been caused after first treatment has been delivered"
            },
            "type": "ListItem",
            "sequence_num": 24
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 90.0,
                "text": "However, a more pro-active approach, with the intention of mitigating any possible harm caused by delay, would be to implement a review by the clinical team of any patient waiting beyond a defined time on the diagnostic and treatment pathway to ensure that they are not coming to excess harm as a result of the long wait. Work by East of England Cancer Alliance has suggested this point should be day  on the pathway."
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.8,
                "text": "Not all patients whose diagnosis and/ or treatment is delayed beyond that which is clinically desirable will breach constitutional standards or be waiting a long time on a cancer pathway. This may occur particularly during a pandemic when waits for access to routine care may be long. The suspicion of cancer may only be become apparent at first routine out-patient appointment and therefore, although diagnostics and treatment from the point of \u2018consultant upgrade' may meet constitution standards, the patient has waited a significant time for these from first, routine referral."
            },
            "type": "ListItem",
            "sequence_num": 26
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.9,
                "text": "Clinical harm can be defined as unintended injury resulting from or contributed to by medical care that requires additional monitoring, treatment or hospitalisation or that results in death"
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Possible harm as a result of delayed cancer diagnosis may be physical or psychological"
            },
            "type": "ListItem",
            "sequence_num": 28
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.11,
                "text": "While possible physical harm is difficult to define, it is generally accepted, nationally, as being indicated where a patient has undergone more, or different treatment, as a result of the delay, or where the patient has suffered more problems because of the delay than would otherwise be expected as a result of the disease."
            },
            "type": "ListItem",
            "sequence_num": 29
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.12,
                "text": "Waiting for a cancer diagnosis and/ or treatment is often an anxious time for patients and families and any delay may result in excess psychological harm. Psychological harm is a type of damage to the mind that occurs as a result of a severely distressing event. Harm could be the result of an overwhelming amount of stress that exceeds one's ability to cope,"
            },
            "type": "ListItem",
            "sequence_num": 30
        },
        {
            "data": {
                "is_heading": 0,
                "text": "or  integrate  the  emotions  involved  with  that  experience.  Defining  psychological  harm caused by the delay, over and above that caused by a cancer diagnosis and treatment is difficult, but generally accepted to be mitigated by support from the clinical team, often the clinical nurse specialist. No harm is therefore usually accepted as being the absence of any clear evidence of harm from the delay (PALS concerns, complaints) along with evidence of support from the clinical team"
            },
            "type": "ListItem",
            "sequence_num": 31
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            },
            "type": "ListItem",
            "sequence_num": 32
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this document is to outline the approach to assessing for, and mitigating against, possible harm in patients who have a delay in cancer diagnosis and treatment when:"
            },
            "type": "ListItem",
            "sequence_num": 33
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 31.0,
                "text": "The patient has been diagnosed with and treated for cancer but there has been a delay causing a breach of the 62 or  day constitutional standard"
            },
            "type": "ListItem",
            "sequence_num": 34
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient is being managed on a cancer pathway and there is likely to be a significant delay to diagnosis and/ or treatment"
            },
            "type": "ListItem",
            "sequence_num": 35
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The patient has not been referred on an urgent cancer referral pathway and has waited a significant time before  subsequent diagnosis and management on an urgent cancer pathway"
            },
            "type": "ListItem",
            "sequence_num": 36
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            },
            "type": "ListItem",
            "sequence_num": 37
        },
        {
            "type": "table",
            "sequence_num": 38,
            "data": {
                "num_rows": 10,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "2W(eek) W(ait) referral"
                    },
                    {
                        "text": "GP/GDP/Optometrist referral for suspected cancer requiring appointment within 14 days."
                    },
                    {
                        "text": "Cancer Waiting Times (CWT)"
                    },
                    {
                        "text": "Cancer Waiting Times measure the NHS' performance against the national NHS Constitution Standards to monitor the timely delivery of services to patients."
                    },
                    {
                        "text": "Consultant Upgrade"
                    },
                    {
                        "text": "Hospital specialists have the right to ensure that patients who are not referred urgently as suspected cancer referrals or through the screening programmes, but who have symptoms or signs indicating a high suspicion of cancer, are managed on the 62 day pathway. This can be achieved by upgrading the patients onto a 62 day upgrade pathway."
                    },
                    {
                        "text": "Decision to Treat (DTT)"
                    },
                    {
                        "text": "A clinical decision is taken to treat the patient."
                    },
                    {
                        "text": "Executive Review Group (ERG)"
                    },
                    {
                        "text": "Clinically led group that determines the level of investigation required for incidents that have occurred. This group also signs off root cause analysis investigations and action plans as a result of serious incidents, never events and internal investigations."
                    },
                    {
                        "text": "First Definitive Treatment (FDT)"
                    },
                    {
                        "text": "An intervention intended to manage a patient's condition, disease or injury and avoid further intervention. What constitutes First Definitive Treatment is a matter for clinical judgment, in consultation with others as appropriate, including the patient."
                    },
                    {
                        "text": "Local Harm Review Panel (LHRP)"
                    },
                    {
                        "text": "Clinically led panel to review/validate/action completed harm reviews and develop lessons learnt or actions for system where applicable"
                    },
                    {
                        "text": "Multi-disciplinary Team (MDT)"
                    },
                    {
                        "text": "An MDT comprises of medical and non-medical professionals who are responsible for the cancer patient's care. It includes clinicians from a variety of disciplines, the exact constituent are described for each tumour site as part of Quality Surveillance requirements."
                    },
                    {
                        "text": "Patient Tracking List (PTL)"
                    },
                    {
                        "text": "A report used to ensure the maximum waiting time targets are achieved by identifying the patient wait time along that pathways and patients who are at risk of being treated outside the pathway requirements"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 39,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Root Cause Analysis (RCA)"
                    },
                    {
                        "text": "Root cause analysis (RCA) was developed for the health services to promote a systematic approach to the investigation of serious incidents. A good RCA investigation will identify any underlying system and process issues that may have caused or contributed to the incident."
                    },
                    {
                        "text": "Somerset Cancer Registry (SCR)"
                    },
                    {
                        "text": "Trust Cancer Systems"
                    },
                    {
                        "text": "Serious Incident (SI)"
                    },
                    {
                        "text": "An incident that occurred in relation to NHS-funded services and care resulting in unexpected or avoidable death, harm or injury to patient, carer, staff or visitor."
                    },
                    {
                        "text": "Screening referral"
                    },
                    {
                        "text": "A referral received following an investigation as part of a screening programme (Breast, Bowel or Cervical)."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Role & Responsibilities within the Trust"
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "MSE Cancer Committee:"
            },
            "type": "ListItem",
            "sequence_num": 41
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that the number of 62+ day breaches by tumour site is a standing agenda item. The data will include completion performance for hospital and breakdown by tumour site"
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Receive and monitor the tumour site exception reports as a standing agenda item, ensuring action is taken to mitigate avoidable delays"
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Receive a paper incorporating the outcome and themes from LHRPs which will be presented to the Quality Governance Committee"
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalate and share, as appropriate, any themes/learning with the Quality Improvement Board (formally CQRG) and the MSE Health and Care Partnership Cancer, Palliative and End of Life Care Board"
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Review all cases where a Serious Incident (SI) is declared."
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "Directorate / Divisional Governance Groups:"
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Maintain oversight of all Harm Reviews relevant to their directorate, oversee and collate reports for all Serious Incidents"
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that the reviews are completed and any actions/learning are shared"
            },
            "type": "ListItem",
            "sequence_num": 49
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure themes and trends are incorporated into the individual action plans"
            },
            "type": "ListItem",
            "sequence_num": 50
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "Chief Executive:"
            },
            "type": "ListItem",
            "sequence_num": 51
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 62.0,
                "text": "Has overall responsibility for ensuring that the Trust has robust process in place for harm reviews, oversight of completion, ensuring lessons learnt and actions identified are taken within the organisation. Ensures that there is a process in place to pro-actively manage and mitigate possible harm, both physical and psychological, in patients who are waiting over  days for cancer treatment"
            },
            "type": "ListItem",
            "sequence_num": 52
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "Managing Director:"
            },
            "type": "ListItem",
            "sequence_num": 53
        },
        {
            "data": {
                "is_heading": 0,
                "text": "As the site's accountable officer is responsible for ensuring the hospital has robust, complete and up  to  date  procedures  in  place  to  govern  and  guide  activities  so  that  legal  and  national requirements are met. Ensures that all patients on a cancer PTL are being managed pro-actively to avoid harm"
            },
            "type": "ListItem",
            "sequence_num": 54
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.5,
                "text": "Director of Operations:"
            },
            "type": "ListItem",
            "sequence_num": 55
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Accountable for  planned  care  performance,  actions  taken  to  mitigate  non-performance  and ensuring that each responsible service is compliant with governance arrangements in place for their area of responsibility"
            },
            "type": "ListItem",
            "sequence_num": 56
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.6,
                "text": "Associate/Deputy Director of Nursing for Cancer:"
            },
            "type": "ListItem",
            "sequence_num": 57
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Accountable for maintaining quality of care in cancer. Oversight of serious incidents and resulting root cause analysis"
            },
            "type": "ListItem",
            "sequence_num": 58
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring Harm Reviews happen in line with SOP"
            },
            "type": "ListItem",
            "sequence_num": 59
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure any lessons learnt/actions are followed up and completed"
            },
            "type": "ListItem",
            "sequence_num": 60
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.7,
                "text": "Associate Directors of Operations, Service Managers & Divisional Clinical Directors:"
            },
            "type": "ListItem",
            "sequence_num": 61
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Accountable for overseeing compliance with this SOP. Ensuring that effective processes are in place to manage patient care and treatment that meet national, local and NHS Constitution targets and standards for each specialty within the relevant division"
            },
            "type": "ListItem",
            "sequence_num": 62
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.8,
                "text": "Medical Director for Cancer / Site Medical Director:"
            },
            "type": "ListItem",
            "sequence_num": 63
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Expected to chair the harm review panel meetings"
            },
            "type": "ListItem",
            "sequence_num": 64
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Expected to sign off and confirm the following on the breach report:"
            },
            "type": "ListItem",
            "sequence_num": 65
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.9,
                "text": "Consultants:"
            },
            "type": "ListItem",
            "sequence_num": 66
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for managing patient care and treatment, working with their Directors/Associate Directors, Service Managers and clinical colleagues to ensure that this is provided within timescales laid down in national, local and NHS constitution targets and standards"
            },
            "type": "ListItem",
            "sequence_num": 67
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for completion of clinical harm review for patients breaching cancer standards within 2 weeks of receipt from governance lead."
            },
            "type": "ListItem",
            "sequence_num": 68
        },
        {
            "data": {
                "is_heading": 0,
                "text": "They should attend LHRP or arrange for clinical deputy to attend on their behalf"
            },
            "type": "ListItem",
            "sequence_num": 69
        },
        {
            "data": {
                "is_heading": 0,
                "text": "They should decide whether the breach was avoidable or unavoidable and decide what level of harm is associated with the breach"
            },
            "type": "ListItem",
            "sequence_num": 70
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 90.0,
                "text": "Responsible for ensuring a clinical review of any patient under their care who is on or beyond day  of a cancer pathway"
            },
            "type": "ListItem",
            "sequence_num": 71
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Tumour site pathway directors:"
            },
            "type": "ListItem",
            "sequence_num": 72
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Should have site of the harm review process within their tumour site"
            },
            "type": "ListItem",
            "sequence_num": 73
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for reporting themes from Harm reviews to MSE Cancer Committee"
            },
            "type": "ListItem",
            "sequence_num": 74
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for ensuring themes/ learning from harm reviews is incorporated into pathway and quality improvement work in their tumour site, including discussion at Network Cancer Groups when relevant"
            },
            "type": "ListItem",
            "sequence_num": 75
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.11,
                "text": "Clinical Nurse Specialists:"
            },
            "type": "ListItem",
            "sequence_num": 76
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for supporting patients through the cancer pathway"
            },
            "type": "ListItem",
            "sequence_num": 77
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Responsible for clearly documenting when there has been clinical intervention or psychological support provided to patient at any point along their pathway"
            },
            "type": "ListItem",
            "sequence_num": 78
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.12,
                "text": "Cancer Services:"
            },
            "type": "ListItem",
            "sequence_num": 79
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Co-ordinate the harm review process."
            },
            "type": "ListItem",
            "sequence_num": 80
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Complete Cancer RCA timeline once first treatment is complete"
            },
            "type": "ListItem",
            "sequence_num": 81
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Report breach onto incident reporting system."
            },
            "type": "ListItem",
            "sequence_num": 82
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.13,
                "text": "Patient Safety Team:"
            },
            "type": "ListItem",
            "sequence_num": 83
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To support timely review by the ERG where the Harm Review Panel has identified of patient harm graded as moderate or above."
            },
            "type": "ListItem",
            "sequence_num": 84
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To support declaration in line with the National Serious Incident Framework."
            },
            "type": "ListItem",
            "sequence_num": 85
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.14,
                "text": "Governance Managers/Leads:"
            },
            "type": "ListItem",
            "sequence_num": 86
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Co-ordinate the reviews, ensuring the relevant Clinician receives the appropriate documentation within one week of receipt"
            },
            "type": "ListItem",
            "sequence_num": 87
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure that clinical review is undertaken and clinical sign off takes place for each breach"
            },
            "type": "ListItem",
            "sequence_num": 88
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Quality check completed reviews before forwarding onto the harm panel for sign off"
            },
            "type": "ListItem",
            "sequence_num": 89
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Return the completed Clinical Harm Review to the Harm Review Co-ordinator within one week of completion by clinician"
            },
            "type": "ListItem",
            "sequence_num": 90
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalate the incident if harm is found, following trust SI process"
            },
            "type": "ListItem",
            "sequence_num": 91
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Close incidents following confirmation of \u2018no harm' following that harm panel"
            },
            "type": "ListItem",
            "sequence_num": 92
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.15,
                "text": "Clinical Service Managers:"
            },
            "type": "ListItem",
            "sequence_num": 93
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Review  the  RCA for  each  patient  within their specialty, ensuring  it  is a  true and accurate representation of the patient journey"
            },
            "type": "ListItem",
            "sequence_num": 94
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Share breach reports and learning outcomes with their specialty teams"
            },
            "type": "ListItem",
            "sequence_num": 95
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensure trends, themes and actions are captured and presented at the clinical governance boards"
            },
            "type": "ListItem",
            "sequence_num": 96
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Attend the Harm Review Panel as required and take any remedial actions or pathway changes for implementation"
            },
            "type": "ListItem",
            "sequence_num": 97
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.16,
                "text": "Cancer Informatics / Data Lead:"
            },
            "type": "ListItem",
            "sequence_num": 98
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Produce monthly data on submitted breaches"
            },
            "type": "ListItem",
            "sequence_num": 99
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Enter MDS onto central harm review spreadsheet"
            },
            "type": "ListItem",
            "sequence_num": 100
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.17,
                "text": "Harm Review Co-Ordinator:"
            },
            "type": "ListItem",
            "sequence_num": 101
        },
        {
            "data": {
                "is_heading": 0,
                "text": "To receive completed harm reviews from relevant divisions"
            },
            "type": "ListItem",
            "sequence_num": 102
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Co-ordinate the LHRP, including room booking and diary requests"
            },
            "type": "ListItem",
            "sequence_num": 103
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Document outcomes, learning, themes and actions from LHRP"
            },
            "type": "ListItem",
            "sequence_num": 104
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Liaise with the Patient Safety team regarding incidents where harm is identified at the LHRP and requires investigation through ERG."
            },
            "type": "ListItem",
            "sequence_num": 105
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Feedback outcomes to the relevant division for action"
            },
            "type": "ListItem",
            "sequence_num": 106
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Update divisions on outcomes, prompting them to close relevant incidents"
            },
            "type": "ListItem",
            "sequence_num": 107
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Update spreadsheet with incident numbers/dates and outcomes"
            },
            "type": "ListItem",
            "sequence_num": 108
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Key Elements of Policy / Guideline"
            },
            "type": "ListItem",
            "sequence_num": 109
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "All patients who are diagnosed with cancer and who receive their first treatment more than 62 days after an urgent cancer referral from primary care, after a \u2018consultant upgrade' from secondary care or through a screening programme will be identified by the Cancer Team. A RCA process will be undertaken to understand the delays within that individual patient pathway and a Harm Review will be performed as outlined in the Cancer Harm Review Process SOP (summarised in appendix 1)."
            },
            "type": "ListItem",
            "sequence_num": 110
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 31.0,
                "text": "All patients who receive first cancer treatment more than  days after a decision to treat has been made will be also be identified by the Cancer Team. An RCA and a Harm Review will be performed as outlined in the Cancer Harm Review Process SOP."
            },
            "type": "ListItem",
            "sequence_num": 111
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "Any patient whose care does not meet clinically acceptable waiting times, despite not breaching any constitutional standard, will receive an RCA and Harm Review as outlined in the Cancer Harm Review Process SOP."
            },
            "type": "ListItem",
            "sequence_num": 112
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "Any patient who has been referred on a routine pathway but is subsequently found to have cancer will have a harm review undertaken, even if treatment has not breached a cancer constitutional standard, if they have waited more than 3 months from referral to consultant upgrade to a cancer pathway."
            },
            "type": "ListItem",
            "sequence_num": 113
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.5,
                "text": "An  initial  assessment  for  possible  harm  will  be  based  on  any  positive  answer  to  the following questions:"
            },
            "type": "ListItem",
            "sequence_num": 114
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Was a tumour thought to be operable now inoperable as a result of the delay?"
            },
            "type": "ListItem",
            "sequence_num": 115
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay meant that patient has had to have more radical surgery than first anticipated?"
            },
            "type": "ListItem",
            "sequence_num": 116
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay meant that disease progression has precluded some treatment options that would have been applicable?"
            },
            "type": "ListItem",
            "sequence_num": 117
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay in treatment meant that a patient has loss of functionality that is greater than anticipated, commensurate with their disease?"
            },
            "type": "ListItem",
            "sequence_num": 118
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Are you aware of/has there been any prolonged psychological harm (28 days or more)?"
            },
            "type": "ListItem",
            "sequence_num": 119
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.6,
                "text": "Additionally, the harm review will ask if the patient had undergone any investigations in the last 12 months for the same symptoms, prior to this current referral."
            },
            "type": "ListItem",
            "sequence_num": 120
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.7,
                "text": "Assessment of possible harm is made by an expert clinical team and reviewed by a Harm Review Panel with a membership comprising of:"
            },
            "type": "ListItem",
            "sequence_num": 121
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Site Medical Director (Chair)"
            },
            "type": "ListItem",
            "sequence_num": 122
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Medical Director for Cancer (Deputy Chair)"
            },
            "type": "ListItem",
            "sequence_num": 123
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Associate/Deputy Director of Nursing for Cancer"
            },
            "type": "ListItem",
            "sequence_num": 124
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer Service Manager"
            },
            "type": "ListItem",
            "sequence_num": 125
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Consultant undertaking clinical harm review"
            },
            "type": "ListItem",
            "sequence_num": 126
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Operational Service Manager for the relevant tumour site service"
            },
            "type": "ListItem",
            "sequence_num": 127
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patient Safety Manager"
            },
            "type": "ListItem",
            "sequence_num": 128
        },
        {
            "data": {
                "is_heading": 0,
                "text": "CCG representative"
            },
            "type": "ListItem",
            "sequence_num": 129
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS Specialised Commissioning representative"
            },
            "type": "ListItem",
            "sequence_num": 130
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Primary Care representative"
            },
            "type": "ListItem",
            "sequence_num": 131
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Harm Review Co-ordinator"
            },
            "type": "ListItem",
            "sequence_num": 132
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.8,
                "text": "Where the possibility of harm is raised by the assessing clinician or Harm Review Panel the case is escalated as a possible SI through the incident reporting process and Patient Safety Team to the ERG for review."
            },
            "type": "ListItem",
            "sequence_num": 133
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.9,
                "text": "An SI is reported when there is felt to have been unexpected or avoidable death, harm or injury to patient as a result of the delay to diagnosis and/or treatment"
            },
            "type": "ListItem",
            "sequence_num": 134
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Where harm is likely to have occurred Duty of Candour is applied and is auditable"
            },
            "type": "ListItem",
            "sequence_num": 135
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.11,
                "text": "The NRLS principles are followed in relation to both physical and psychological harm (Appendix 3)"
            },
            "type": "ListItem",
            "sequence_num": 136
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.12,
                "text": "Learning and service improvement planning from the Tumour site Harm Reviews will be:"
            },
            "type": "ListItem",
            "sequence_num": 137
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Disseminated through service clinical governance meetings"
            },
            "type": "ListItem",
            "sequence_num": 138
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Reported to MSE Cancer Committee as part of the Tumour Pathway Director monthly reports"
            },
            "type": "ListItem",
            "sequence_num": 139
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Discussed through Network Cancer Groups to provide support and challenge for clinical teams"
            },
            "type": "ListItem",
            "sequence_num": 140
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.13,
                "text": "Themes from the Harm Review process will be presented quarterly to MSE Cancer Committee"
            },
            "type": "ListItem",
            "sequence_num": 141
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.14,
                "text": "All patients waiting for diagnostics to diagnose or rule out cancer or waiting for cancer treatment will be reviewed at least weekly at the cancer patient tracking list meeting"
            },
            "type": "ListItem",
            "sequence_num": 142
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.15,
                "text": "Any patient who has been on a cancer pathway for 90 days or more is escalated to the clinical team for:"
            },
            "type": "ListItem",
            "sequence_num": 143
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Clinical review to ensure that immediate action is not necessary to mitigate against potential physical harm"
            },
            "type": "ListItem",
            "sequence_num": 144
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Contact and support from the clinical nurse specialist if not already in place to mitigate against potential psychological harm"
            },
            "type": "ListItem",
            "sequence_num": 145
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.16,
                "text": "Any patient who has been waiting for more than 104 days for diagnosis or treatment will be escalated at the PTL meeting through the hospital site Managing Directors to the Trust Chief Executive"
            },
            "type": "ListItem",
            "sequence_num": 146
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.17,
                "text": "In order to minimise long waits for diagnosis and treatment, national best practice pathways, and any adaptions recommended in special circumstances (eg pandemics) will be adopted."
            },
            "type": "ListItem",
            "sequence_num": 147
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Training Requirements"
            },
            "type": "ListItem",
            "sequence_num": 148
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "All staff involved in the Cancer and Harm Review pathways will have specific induction in relation to the implementation of this policy and the associated procedure."
            },
            "type": "ListItem",
            "sequence_num": 149
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Monitoring and Audit"
            },
            "type": "ListItem",
            "sequence_num": 150
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Outlined below is the Trust's process of monitoring compliance with, and the effectiveness of the document's main points."
            },
            "type": "ListItem",
            "sequence_num": 151
        },
        {
            "type": "table",
            "sequence_num": 152,
            "data": {
                "num_rows": 5,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Aspect of compliance or effectiveness being monitored"
                    },
                    {
                        "text": "Monitoring Method"
                    },
                    {
                        "text": "Individual department responsible for the monitoring"
                    },
                    {
                        "text": "Frequency of the monitoring activity"
                    },
                    {
                        "text": "Group / Committee / forum which will receive the findings/moni toring report"
                    },
                    {
                        "text": "Committee / individual responsible for ensuring the actions are completed"
                    },
                    {
                        "text": "Cancer Harm Reviews"
                    },
                    {
                        "text": "Review of all breached 31/62 day cancer pathways"
                    },
                    {
                        "text": "Cancer Division"
                    },
                    {
                        "text": "Fortnightly"
                    },
                    {
                        "text": "Cancer Harm Review Panel MSE Cancer Committee"
                    },
                    {
                        "text": "Cancer Harm Review Panel MSE Cancer Committee"
                    },
                    {
                        "text": "Cancer PTL"
                    },
                    {
                        "text": "Meeting"
                    },
                    {
                        "text": "Cancer Division"
                    },
                    {
                        "text": "Weekly"
                    },
                    {
                        "text": "MSE Cancer Committee"
                    },
                    {
                        "text": "MSE Cancer Committee"
                    },
                    {
                        "text": "Themes and learning from completed harm reviews"
                    },
                    {
                        "text": "Report"
                    },
                    {
                        "text": "Harm review co-ordinator"
                    },
                    {
                        "text": "Quarterly"
                    },
                    {
                        "text": "MSE Cancer Committee and Quality Improvement Board"
                    },
                    {
                        "text": "MSE Cancer Committee"
                    },
                    {
                        "text": "Harm Review Progress and Outcomes"
                    },
                    {
                        "text": "Report"
                    },
                    {
                        "text": "Cancer Division"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "MSE Cancer Committee and Quality Improvement Board"
                    },
                    {
                        "text": "MSE Cancer Committee"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Equality Impact Assessment"
            },
            "type": "ListItem",
            "sequence_num": 153
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            },
            "type": "ListItem",
            "sequence_num": 154
        },
        {
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 4)"
            },
            "type": "ListItem",
            "sequence_num": 155
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 156
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NHS Constitution: https://www.gov.uk/government/publications/the-nhs-constitution-for-england"
            },
            "type": "ListItem",
            "sequence_num": 157
        },
        {
            "data": {
                "is_heading": 0,
                "text": "CWT guidance: https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data- collections/cancerwaitingtimescwt"
            },
            "type": "ListItem",
            "sequence_num": 158
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Cancer Harm Review Process"
            },
            "type": "ListItem",
            "sequence_num": 159
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Referral received by the Trust"
            },
            "type": "ListItem",
            "sequence_num": 160
        },
        {
            "type": "image",
            "sequence_num": 161,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.003.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Patient treated after day 31or 62 \u2013 Somerset updated \u2013 pathway closed. Breach report completed with timeline and incident reported on Trust system"
            },
            "type": "ListItem",
            "sequence_num": 162
        },
        {
            "type": "image",
            "sequence_num": 163,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.004.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Pathway  timeline  compiled  and  request  (through  the  Incident  Management  System)  for completion of a Clinical Harm Review assigned to the Directorate Governance Manager/Lead where a breach has occurred. Harm review to determine:"
            },
            "type": "ListItem",
            "sequence_num": 164
        },
        {
            "type": "image",
            "sequence_num": 165,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.005.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has the patient undergone any investigations in the last 12 months for the same symptoms, prior to this current referral?"
            },
            "type": "ListItem",
            "sequence_num": 166
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Was a tumour thought to be operable now inoperable as a result of the delay?"
            },
            "type": "ListItem",
            "sequence_num": 167
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay meant that patient has had to have more radical surgery than first anticipated?"
            },
            "type": "ListItem",
            "sequence_num": 168
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay meant that disease progression has precluded some treatment options that would have been applicable?"
            },
            "type": "ListItem",
            "sequence_num": 169
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has a delay in treatment meant that a patient has loss of functionality that is greater than anticipated, commensurate with their disease?"
            },
            "type": "ListItem",
            "sequence_num": 170
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Are you aware of/has there been any prolonged Psychological harm (28 days or more)"
            },
            "type": "ListItem",
            "sequence_num": 171
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Notification of pending harm review sent to the Harm Review co-ordinator"
            },
            "type": "ListItem",
            "sequence_num": 172
        },
        {
            "type": "image",
            "sequence_num": 173,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.006.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Clinical Harm Review presented at the Local Harm Review Panel for agreement of whether the patient has experienced harm due to the delay in treatment during the pathway"
            },
            "type": "ListItem",
            "sequence_num": 174
        },
        {
            "type": "image",
            "sequence_num": 175,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.007.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If harm to the patient is identified it is escalated to the Executive Review Group (through Patient Safety) for decision to declare as a Serious Incident where duty of candour is applied as appropriate"
            },
            "type": "ListItem",
            "sequence_num": 176
        },
        {
            "type": "image",
            "sequence_num": 177,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.008.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "RCA to be updated with any agreed amendments from the Harm Review Panel. The Incident Management System to be amended as appropriate"
            },
            "type": "ListItem",
            "sequence_num": 178
        },
        {
            "type": "image",
            "sequence_num": 179,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.009.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Meeting and action log to be circulated to panel members and Clinicians in attendance"
            },
            "type": "ListItem",
            "sequence_num": 180
        },
        {
            "type": "image",
            "sequence_num": 181,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.010.png"
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All learning and themes identified through the harm review process shared with MSE Cancer Committee and through the reporting structure as appropriate (appendix 2)"
            },
            "type": "ListItem",
            "sequence_num": 182
        },
        {
            "type": "image",
            "sequence_num": 183,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.011.png"
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Cancer Harm Review Reporting Structure"
            },
            "type": "ListItem",
            "sequence_num": 184
        },
        {
            "type": "image",
            "sequence_num": 185,
            "data": {
                "url": "MSEPO-21008 Cancer Harm Assessment, Mitigation And Review Policy 1.0.012.jpeg"
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Harm definitions and interpretation (NRLS)"
            },
            "type": "ListItem",
            "sequence_num": 186
        },
        {
            "type": "table",
            "sequence_num": 187,
            "data": {
                "num_rows": 4,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": "Grading"
                    },
                    {
                        "text": "NRLS Definition"
                    },
                    {
                        "text": "Physical Harm"
                    },
                    {
                        "text": "Psychological harm"
                    },
                    {
                        "text": "No Harm"
                    },
                    {
                        "text": "No harm (Impact prevented) \u2013 Any patient safety incident that had the potential to cause harm but was prevented, resulting in no harm to people receiving NHS- funded care. This may be locally termed a \u2018near miss'. No harm (impact not prevented) - Any patient safety incident that ran to completion but no harm occurred to people receiving NHS funded care."
                    },
                    {
                        "text": "Excessive wait but no change in symptoms from referral expected Pathway issue is administrative and patient has not come to harm or is not expected to come to harm Patient died of a condition other than referral relates to, where the treatment provided would not have offered longer life."
                    },
                    {
                        "text": "<2 cancellations by hospital whilst on outpatient waiting list <2 cancellations by hospital whilst on inpatient waiting list (Impact of harm may be greater if vulnerable patient \u2013 Severe Mental Illness, LD or Dementia or if patient has been shielding / isolating prior to inpatient TCI date \u2013 consider low or moderate harm)"
                    },
                    {
                        "text": "Low Harm"
                    },
                    {
                        "text": "Any unexpected or unintended incident that required extra observation or minor treatment and caused minimal harm to one or more persons receiving NHS-funded care."
                    },
                    {
                        "text": "Prolongation of moderate or severe symptoms present on initial consultation Some increase in medication or treatment Some loss of function from initial referral Prolonged loss of function present on initial consultation"
                    },
                    {
                        "text": ">2 cancellations by hospital whilst on out-patient waiting list. >2 cancellations by hospital whilst on in-patient waiting list. Prolonged moderate or severe pain for a continuous period of >28days relating to index condition Prolonged need for care Psychological distress for a continuous period of >28 days relating to index condition For children \u2013consider developmental or educational delay impact due to time waiting."
                    },
                    {
                        "text": "Moderate Harm"
                    },
                    {
                        "text": "Any unexpected or unintended incident that resulted in a moderate increase in treatment, possible surgical intervention, cancelling of treatment, or transfer to another area, and which caused significant but not permanent harm, to one or more persons receiving NHS-funded"
                    },
                    {
                        "text": "Emergency admission related to index condition Loss of visual acuity (not permanent) Significant increase in symptoms Significant increase or change in medication or treatment Significant loss of function from initial referral Treatment plan significantly different to original plan"
                    },
                    {
                        "text": "Patient has needed to seek support from counselling services as a result of a long wait for treatment or to manage symptoms related to index physical condition For children \u2013consider developmental or educational delay impact due to time waiting."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 188,
            "data": {
                "num_rows": 3,
                "num_cols": 4,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "care."
                    },
                    {
                        "text": "requiring more recovery or protracted LoS Missed window of opportunity for particular treatment requiring change to treatment"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Severe Harm"
                    },
                    {
                        "text": "Any unexpected or unintended incident that appears to have resulted in permanent harm to one or more persons."
                    },
                    {
                        "text": "Delayed diagnosis resulting limited / no viable treatment options Progression of cancer Life changing injury as a result of the delay e.g. Loss of Limb /Complete loss of sight"
                    },
                    {
                        "text": "Inpatient admission to MH provider as a result of impact of waiting or symptoms from index physical condition Self-harm used as a way to manage symptoms from index physical condition"
                    },
                    {
                        "text": "Catastrophic Harm"
                    },
                    {
                        "text": "Any unexpected or unintended incident that directly resulted in the death of one or more persons"
                    },
                    {
                        "text": "Death on the waiting list from index condition"
                    },
                    {
                        "text": "Suicide which is linked to the index physical condition."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer Harm Assessment, Mitigation and Review Policy / MSEPO-21008 / 1.0"
            },
            "type": "ListItem",
            "sequence_num": 189
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 190
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Cancer Harm Assessment, Mitigation and Review Policy / MSEPO-21008/ 1.0"
            },
            "type": "ListItem",
            "sequence_num": 191
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 4: Preliminary Equality Analysis"
            },
            "type": "ListItem",
            "sequence_num": 192
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to Cancer Harm Assessment, Mitigation and Review Policy: (please tick all that apply)"
            },
            "type": "ListItem",
            "sequence_num": 193
        },
        {
            "type": "table",
            "sequence_num": 194,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2610 A change to an existing document"
                    },
                    {
                        "text": "\u2612 A change to the way staff work"
                    },
                    {
                        "text": "\u2612 A new document"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 195,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "The process for Harm Reviews has developed significantly since the previous site based procedures. This policy supports the procedural SOP that has been recently released across the MSE."
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "We now have a more robust harm review process which provides monitoring and assurance. This policy clearly defines the guiding principles and responsibilities of the associated procedural SOP for the MSE."
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "It will give Divisions/Directorates reviewing the Cancer pathway the ability to develop action plans based on learning from harm reviews, thus improving patient care and experience, and reducing potential of future patient harm."
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No."
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "MSE Cancer Committee. Refer to pages 1 & 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 196,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Catherine O'Doherty"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Medical Director for Cancer"
                    },
                    {
                        "text": "05 February 2021"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "If you have identified any negative impact in the preliminary analysis above, please request and complete the full Equality Impact Assessment (EIA) from Document Control."
            },
            "type": "ListItem",
            "sequence_num": 197
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 198
        }
    ]
}